JP Morgan Rates Upstream Bio (UPB) hold, $8 Price Target

JP Morgan has downgraded UPB to a 'hold' rating with a price target of $8, a 31.15% upside from the current price.

By EarningsIQ Research Desk · Published Jun 13, 2026, 10:00 AM EDT · Updated Jun 14, 2026, 1:00 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

JP Morgan rated Upstream Bio, Inc. ($UPB) "hold" with a $8 price target on June 12, 2026.

Since the rating, $UPB is up 3.3% after 1 week, up 19.3% after 1 month and down 54.8% to date (from the $6.10 close on Jun 12, 2026).

UPB Upstream Bio, Inc.

$2.76 -89.80% year to date

Daily close · Oct 16, 2026

Key Points

JP Morgan downgraded UPB to 'hold' with a new price target of $8 on June 12, 2026.
JP Morgan's $8 price target implies 31.15% upside from Upstream Bio, Inc.'s ($UPB) current $6.10 share price.
UPB shares are trading around $6.1, with recent insider purchases adding interest.
FMR LLC increased its UPB stake by 583,361 shares, while Decheng Capital reduced its holdings by 418,210 shares.

Get $UPB trade alerts by text

We text you when insiders, Congress or big funds trade $UPB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Upstream Bio, Inc. alert may contain errors. Disclosures

On June 12, 2026, JP Morgan downgraded UPB to a 'hold' rating, setting a new price target of $8. This change comes as UPB shares are trading around $6.1. Analyst Tessa Romero led the downgrade, which suggests a more cautious outlook on the stock.

Other Institutional Activity in UPB

FMR LLC grew its holdings in UPB by 583,361 shares, ending with 8,101,563 shares worth about $72.9 million. Meanwhile, Decheng Capital LLC trimmed its position by 418,210 shares, now holding 2,724,868 shares valued at approximately $24.5 million. BlackRock, Inc. slightly increased its stake by 26,185 shares, reaching a total of 3,370,689 shares valued at $30.3 million.

Upstream Bio, Inc. Stock Up 14.2%

UPB shares are currently trading near $6.1. With the recent analyst downgrade and varying institutional activities, the stock remains a point of interest for investors.

12-month forecast

$UPB price target

Upstream Bio, Inc. daily closes and this analyst's $8 target. Not advice.

Insider Buying and Selling at Upstream Bio, Inc.

On June 9, 2026, several insiders, including Marcella Ruddy and Daniella Beckman, each purchased 17,096 shares of UPB. These transactions were not part of a pre-planned trading scheme, indicating a potential vote of confidence from the company's leadership.

Analysts Set New Price Targets

On June 12, 2026, JP Morgan downgraded UPB to a 'hold' with an $8 price target. Earlier, on June 3, 2026, HC Wainwright & Co. initiated coverage with a 'buy' rating and a $36 target. Mizuho maintained its 'buy' rating with a $50 target on May 14, 2026.

Bottom Line

JP Morgan's downgrade of UPB to 'hold' with an $8 target reflects a cautious stance on the stock's prospects. Despite this, recent insider purchases and varied institutional activities suggest ongoing interest. As always, remember that analyst ratings and 13F filings are backward-looking and may not reflect the current market conditions.